Image (37366051 Ccb9 4ce6 9060 0d4fa9e00a66 01)
Enalapril Maleate Tablet
Product Images NDC 50090-6437
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Enalapril Maleate (NDC 50090-6437). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (37366051 Ccb9 4ce6 9060 0d4fa9e00a66 02)
This is a table comparing the incidence of various side effects between a group of people who were given Enataprll and another group who were given Placebo. The table lists various side-effects, such as dizziness, chest pain, and urinary tract infections, and the number of individuals in each group who experienced them.*
Image (37366051 Ccb9 4ce6 9060 0d4fa9e00a66 03)
This text provides dosage guidelines for Creatinine based on the patient's renal status measured by clearance in mL/min. Patients with normal renal function should take an initial dose of 5mg/day. Patients with mild impairment have a clearance of < 80 >30 mU/min and should also take an initial dose of 5mg/day. Moderate to severe impairment of <30 mU/min should take an initial dose of 25mg/day. Dialysis patients should take 25mg/day on dialysis days. This medication has a warning for anaphylactoid reactions during membrane exposure. The dosage on nondialysis days should be adjusted depending on the patient's blood pressure response.*
Label Image (Lbl500906437)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
